{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:39Z","timestamp":1794255879415,"version":"4.9.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03715-z","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:39:37Z","timestamp":1785400777000},"page":"4999-5013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revolutionizing 2L+\u2009Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies"],"prefix":"10.1007","volume":"43","author":[{"given":"Roberto","family":"Mina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"23","key":"3715_CR1","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","volume":"8","author":"MS Ebraheem","year":"2024","unstructured":"Ebraheem MS, Chakraborty R, Rochwerg B, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8(23):5993\u20136002.","journal-title":"Blood Adv"},{"issue":"4","key":"3715_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study. Nat Med. 2025;31(4):1195\u2013202.","journal-title":"Nat Med"},{"issue":"17","key":"3715_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"4","key":"3715_CR4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066\u201377.","journal-title":"Leukemia"},{"issue":"1","key":"3715_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41409-025-02733-9","volume":"61","author":"JF Wu","year":"2026","unstructured":"Wu JF, Estrada-Merly N, Zhou Y, Canales B, Yen TWF, D\u2019Souza A. Multiple myeloma incidence, transplant utilization, and mortality\u2013impact of social vulnerability. Bone Marrow Transplant. 2026;61(1):95\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 2","key":"3715_CR6","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2023-191911","volume":"142","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd alone in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT): primary results of the PERSEUS trial. Blood. 2023;142(suppl 2):LBA-1.","journal-title":"Blood"},{"key":"3715_CR7","unstructured":"Sonneveld P, Zweegman S, Facon T, et al. Modelling long-term progression-free survival in transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. Presented at the 6th European Myeloma Network (EMN) Meeting; April 10\u201312, 2025; Athens, Greece."},{"issue":"1","key":"3715_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/hematology.2020000109","volume":"2020","author":"N van de Donk","year":"2020","unstructured":"van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. Hematol Am Soc Hematol Educ Program. 2020;2020(1):248\u201358.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"3715_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3715_CR10","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","volume":"26","author":"KA Frerichs","year":"2020","unstructured":"Frerichs KA, Broekmans MEC, Marin Soto JA, et al. Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. Clin Cancer Res. 2020;26(9):2203\u201315.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3715_CR11","first-page":"131","volume":"142","author":"S Bird","year":"2023","unstructured":"Bird S, Pawlyn C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood. 2023;142(2):131\u201340.","journal-title":"Blood"},{"key":"3715_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1550644","volume":"15","author":"F Gay","year":"2025","unstructured":"Gay F, Zamagni E, Cole CE, et al. Clinical outcomes associated with anti\u2013CD38-based retreatment in relapsed\/refractory multiple myeloma: a systematic literature review. Front Oncol. 2025;15:1550644.","journal-title":"Front Oncol"},{"issue":"18","key":"3715_CR13","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood"},{"issue":"1","key":"3715_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087.","journal-title":"BMC Cancer"},{"issue":"17","key":"3715_CR15","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.3390\/cancers13174320","volume":"13","author":"L Gengenbach","year":"2021","unstructured":"Gengenbach L, Graziani G, Reinhardt H, et al. Choosing the right therapy for patients with relapsed\/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors. Cancers (Basel). 2021;13(17):4320.","journal-title":"Cancers (Basel)"},{"key":"3715_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/PPA.S496106","volume":"19","author":"S Ailawadhi","year":"2025","unstructured":"Ailawadhi S, Biru Y, Clavreul S, et al. Perspectives of healthcare providers and patients with relapsed\/refractory multiple myeloma on treatment priorities and novel therapies. Patient Prefer Adherence. 2025;19:1089\u2013104.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"3715_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","volume":"64","author":"AS Rosenberg","year":"2023","unstructured":"Rosenberg AS. From mechanism to resistance\u2013changes in the use of dexamethasone in the treatment of multiple myeloma. Leuk Lymphoma. 2023;64(2):283\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3715_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, et al. International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543\u201354.","journal-title":"Leukemia"},{"issue":"10","key":"3715_CR19","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow-up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 2023;10(10):e813\u201324.","journal-title":"Lancet Haematol"},{"issue":"8","key":"3715_CR20","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1600\u20139.","journal-title":"J Clin Oncol"},{"issue":"14","key":"3715_CR21","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Quach H, Mateos MV, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7(14):3739\u201348.","journal-title":"Blood Adv"},{"issue":"1","key":"3715_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","volume":"13","author":"T Martin","year":"2023","unstructured":"Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J. 2023;13(1):72.","journal-title":"Blood Cancer J"},{"issue":"8","key":"3715_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728\u201334.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3715_CR24","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327\u201337.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3715_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000786","volume":"6","author":"P Sonneveld","year":"2022","unstructured":"Sonneveld P, Zweegman S, Cavo M, et al. Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. Hemasphere. 2022;6(10):e786.","journal-title":"Hemasphere"},{"issue":"10262","key":"3715_CR26","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563\u201373.","journal-title":"Lancet"},{"issue":"6","key":"3715_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781\u201394.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3715_CR28","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/cancers17071168","volume":"17","author":"K Mancuso","year":"2025","unstructured":"Mancuso K, Barbato S, Di Raimondo F, et al. Forcing ahead: second-line treatment options for lenalidomide-refractory multiple myeloma. Cancers (Basel). 2025;17(7):1168.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3715_CR29","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/bjh.19627","volume":"205","author":"MA Hartley-Brown","year":"2024","unstructured":"Hartley-Brown MA, Weisel K, Bitetti J, et al. Multiple myeloma refractory to lenalidomide: a systematic literature review of trials and real-world evidence. Br J Haematol. 2024;205(3):780\u201397.","journal-title":"Br J Haematol"},{"key":"3715_CR30","unstructured":"CARVYKTI\u00ae (ciltacabtagene autoleucel) suspension for intravenous infusion [package insert]. Horsham, PA, USA: Janssen Biotech, Inc.; 2024."},{"key":"3715_CR31","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed\/refractory multiple myeloma. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma\/."},{"key":"3715_CR32","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed\/refractory multiple myeloma. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma\/."},{"key":"3715_CR33","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed\/refractory multiple myeloma. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-japan\/."},{"key":"3715_CR34","unstructured":"BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use [package insert]. Durham, NC, USA: GSK; 2025."},{"issue":"2","key":"3715_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","volume":"27","author":"H Einsele","year":"2026","unstructured":"Einsele H, San-Miguel J, Dhakal B, et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2026;27(2):254\u201368.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3715_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.20517\/cdr.2022.138","volume":"6","author":"V Sammartano","year":"2023","unstructured":"Sammartano V, Franceschini M, Fredducci S, et al. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 2023;6(1):169\u201381.","journal-title":"Cancer Drug Resist"},{"issue":"5","key":"3715_CR37","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","volume":"24","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S. Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2024;24(5):e217\u201325.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"3715_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"3715_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321.","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"3715_CR40","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1182\/blood-2025-2264","volume":"146","author":"S Trudel","year":"2025","unstructured":"Trudel S, Beksac M, Pour L, et al. Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study. Blood. 2025;146(suppl 1):2264.","journal-title":"Blood"},{"key":"3715_CR41","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2147\/DDDT.S267404","volume":"15","author":"M Offidani","year":"2021","unstructured":"Offidani M, Corvatta L, More S, Olivieri A. Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety. Drug Des Devel Ther. 2021;15:2401\u201315.","journal-title":"Drug Des Devel Ther"},{"key":"3715_CR42","unstructured":"US Food and Drug Administration. Belantamab mafodotin BLA 761440 Oncologic Drugs Advisory Committee meeting. FDA introductory comments. Available from: https:\/\/www.fda.gov\/media\/187657\/download."},{"issue":"10","key":"3715_CR43","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/ajh.70015","volume":"100","author":"E Terpos","year":"2025","unstructured":"Terpos E, Trudel S, Mateos MV, et al. Practical guidance on clinical management of belantamab mafodotin-associated ocular events. Am J Hematol. 2025;100(10):1839\u201350.","journal-title":"Am J Hematol"},{"issue":"8","key":"3715_CR44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","volume":"394","author":"LJ Costa","year":"2026","unstructured":"Costa LJ, Bahlis NJ, Perrot A, et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. 2026;394(8):739\u201352.","journal-title":"N Engl J Med"},{"issue":"16 suppl","key":"3715_CR45","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, van de Donk NWCJ, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(16 suppl):7540.","journal-title":"J Clin Oncol"},{"issue":"22","key":"3715_CR46","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(22):2702\u201312.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3715_CR47","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"6","key":"3715_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"2","key":"3715_CR49","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","volume":"26","author":"HC Lee","year":"2026","unstructured":"Lee HC, Zonder JA, Dhodapkar MV, et al. Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses. Clin Lymphoma Myeloma Leuk. 2026;26(2):e201\u201312.e8.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"Suppl 1","key":"3715_CR50","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/blood-2024-208192","volume":"144","author":"HM Prince","year":"2024","unstructured":"Prince HM, Bahlis NJ, Rodr\u00edguez-Otero P, et al. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. Blood. 2024;144(Suppl 1):4738.","journal-title":"Blood"},{"issue":"6","key":"3715_CR51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144(6):615\u201328.","journal-title":"Blood"},{"key":"3715_CR52","unstructured":"Mateos MV, Bahlis NJ, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd\/DVd) in patients with relapsed refractory multiple myeloma (RRMM): results of MajesTEC-3. Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition; December 6\u20139, 2025; Orlando, FL, USA."},{"issue":"4","key":"3715_CR53","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"3715_CR54","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143\u201361.","journal-title":"Lancet Haematol"},{"issue":"6","key":"3715_CR55","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023;4(6):440\u201351.","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"3715_CR56","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1182\/blood-2024-203609","volume":"144","author":"M Balev","year":"2024","unstructured":"Balev M, Shah N, Shah MR, et al. Efficacy and safety of teclistamab in relapsed refractory multiple myeloma: long-term follow-up from a real world multi-institutional cohort. Blood. 2024;144(suppl 1):3781\u20132.","journal-title":"Blood"},{"issue":"suppl 1","key":"3715_CR57","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/blood-2024-206155","volume":"144","author":"L Cani","year":"2024","unstructured":"Cani L, Scott SA, Joseph NS, et al. Risk of infections in multiple myeloma patients treated with bispecific antibodies. Blood. 2024;144(suppl 1):3311.","journal-title":"Blood"},{"key":"3715_CR58","doi-asserted-by":"crossref","unstructured":"Richter J, Gautam S, Yin X, et al. Recent trends in real-world frontline treatment patterns and outcomes for patients with multiple myeloma in the United States. Presented at the 22nd International Myeloma Society (IMS) Annual Meeting & Exposition; September 17\u201320, 2025; Toronto, ON, Canada.","DOI":"10.1016\/S2152-2650(25)03893-5"},{"key":"3715_CR59","unstructured":"ClinicalTrials.gov. A study comparing teclistamab monotherapy versus pomalidomide, bortezomib, dexamethasone (PVd) or carfilzomib, dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (MajesTEC-9). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05572515."},{"issue":"suppl 16","key":"3715_CR60","doi-asserted-by":"publisher","first-page":"TPS8067","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8067","volume":"41","author":"C Touzeau","year":"2023","unstructured":"Touzeau C, Hungria V, Bhutani D, et al. MajesTEC-9: a randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41(suppl 16):TPS8067.","journal-title":"J Clin Oncol"},{"key":"3715_CR61","doi-asserted-by":"publisher","unstructured":"Touzeau C, Mina R, Quach H, et al. Teclistamab in multiple myeloma with one to three previous lines of therapy. N Engl J Med. Published online May 29, 2026. https:\/\/doi.org\/10.1056\/NEJMoa2603870","DOI":"10.1056\/NEJMoa2603870"},{"key":"3715_CR62","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, D\u2019Souza A, Reece D, et al. A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma: updated phase 1b results for daratumumab in combination with teclistamab (a B-cell maturation antigen x CD3 bispecific antibody). Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; June 3\u20137, 2022; Chicago, IL, USA & Virtual.","DOI":"10.1200\/JCO.2022.40.16_suppl.8032"},{"issue":"suppl 1","key":"3715_CR63","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/blood-2024-200181","volume":"144","author":"A D'Souza","year":"2024","unstructured":"D\u2019Souza A, Costa LJ, San-Miguel JF, et al. Teclistamab, daratumumab, and pomalidomide in patients with relapsed\/refractory multiple myeloma: results from the MajesTEC-2 cohort A and TRIMM-2 studies. Blood. 2024;144(suppl 1):495.","journal-title":"Blood"},{"issue":"16 suppl","key":"3715_CR64","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","volume":"42","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Beksac B, Terpos E, et al. Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2024;42(16 suppl):7506.","journal-title":"J Clin Oncol"},{"key":"3715_CR65","doi-asserted-by":"crossref","unstructured":"Raab MS, Weinhold N, Kr\u00f6nke J, et al. Post induction outcomes and updated minimal residual disease analysis from GMMG HD10\/DSMM XX (MajesTEC-5): a study of teclistamab based induction regimens in newly diagnosed multiple myeloma. Presented at the 22nd International Myeloma Society (IMS) Annual Meeting; September 17\u201320, 2025; Toronto, ON, Canada.","DOI":"10.1016\/S2152-2650(25)03417-2"},{"issue":"suppl 1","key":"3715_CR66","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2024-205608","volume":"144","author":"E Zamagni","year":"2024","unstructured":"Zamagni E, Silzle T, \u0160pi\u010dka I, et al. Phase 3 study of teclistamab (Tec) in combination with lenalidomide (Len) and Tec alone versus Len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety run-in (SRI) results from the MajesTEC-4\/EMN30 trial. Blood. 2024;144(suppl 1):494.","journal-title":"Blood"},{"key":"3715_CR67","unstructured":"TALVEY\u2122 (talquetamab-tgvs) injection, for subcutaneous use [package insert]. Horsham, PA, USA: Janssen Biotech, Inc.; 2025."},{"key":"3715_CR68","doi-asserted-by":"publisher","unstructured":"Mina R, Beksac M, Rodr\u00edguez-Otero P, et al. Talquetamab-daratumumab in relapsed or refractory myeloma. N Engl J Med. Published online June 13, 2026. https:\/\/doi.org\/10.1056\/NEJMoa2604657","DOI":"10.1056\/NEJMoa2604657"},{"key":"3715_CR69","unstructured":"ClinicalTrials.gov. A study comparing talquetamab plus pomalidomide, talquetamab plus teclistamab, and elotuzumab, pomalidomide, and dexamethasone or pomalidomide, bortezomib, and dexamethasone in participants with relapsed or refractory myeloma who have received an anti-CD38 antibody and lenalidomide (MonumenTAL-6). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06208150."},{"key":"3715_CR70","unstructured":"ClinicalTrials.gov. A trial to learn how well linvoseltamab works compared to the combination of elotuzumab, pomalidomide and dexamethasone for adult participants with relapsed\/refractory multiple myeloma (LINKER-MM3). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05730036."},{"key":"3715_CR71","unstructured":"ClinicalTrials.gov. A study to learn about the study medicine elranatamab alone and with daratumumab in people with multiple myeloma who have received other treatments (MAGNETISMM-5). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05020236."},{"issue":"5","key":"3715_CR72","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/jcm14051655","volume":"14","author":"E Mavrothalassitis","year":"2025","unstructured":"Mavrothalassitis E, Triantafyllakis K, Malandrakis P, Gavriatopoulou M, Kleber M, Ntanasis-Stathopoulos I. Current treatment strategies for multiple myeloma at first relapse. J Clin Med. 2025;14(5):1655.","journal-title":"J Clin Med"},{"issue":"11","key":"3715_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70260","volume":"9","author":"N van de Donk","year":"2025","unstructured":"van de Donk N, Moreau P, San-Miguel JF, et al. Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: practical guidance from the European Myeloma Network. Hemasphere. 2025;9(11):e70260.","journal-title":"Hemasphere"},{"key":"3715_CR74","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2147\/OTT.S398118","volume":"18","author":"N van de Donk","year":"2025","unstructured":"van de Donk N, Bahlis NJ, Pawlyn C, et al. The role of CELMoD agents in multiple myeloma. Onco Targets Ther. 2025;18:921\u201333.","journal-title":"Onco Targets Ther"},{"key":"3715_CR75","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb announces positive phase 3 results from the SUCCESSOR-2 study of oral mezigdomide in relapsed or refractory multiple myeloma. Available from: https:\/\/news.bms.com\/news\/corporate-financial\/2026\/Bristol-Myers-Squibb-Announces-Positive-Phase-3-Results-from-the-SUCCESSOR-2-Study-of-Oral-Mezigdomide-in-Relapsed-or-Refractory-Multiple-Myeloma\/default.aspx."},{"key":"3715_CR76","unstructured":"ClinicalTrials.gov. A study to evaluate mezigdomide in combination with carfilzomib and dexamethasone (MeziKD) versus carfilzomib and dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (SUCCESSOR-2). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05552976."},{"key":"3715_CR77","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb announces phase 3 EXCALIBER-RRMM study evaluating iberdomide in combination with standard therapies demonstrated a significant improvement in minimal residual disease negativity rates in relapsed or refractory multiple myeloma. Available from: https:\/\/news.bms.com\/news\/corporate-financial\/2025\/Bristol-Myers-Squibb-Announces-Phase-3-EXCALIBER-RRMM-Study-Evaluating-Iberdomide-in-Combination-with-Standard-Therapies-Demonstrated-a-Significant-Improvement-in-Minimal-Residual-Disease-Negativity-Rates-in-Relapsed-or-Refractory-Multiple-Myeloma\/default.aspx."},{"key":"3715_CR78","unstructured":"ClinicalTrials.gov. Open-label study comparing iberdomide, daratumumab and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) (EXCALIBER-RRMM). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04975997."},{"key":"3715_CR79","unstructured":"TECVAYLI\u00ae (teclistamab-cqyv) injection, for subcutaneous use [package insert]. Horsham, PA, USA: Janssen Biotech, Inc.; 2026."},{"issue":"1","key":"3715_CR80","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13(1):116.","journal-title":"Blood Cancer J"},{"issue":"1","key":"3715_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y","volume":"13","author":"SA Scott","year":"2023","unstructured":"Scott SA, Marin EM, Maples KT, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience. Blood Cancer J. 2023;13(1):191.","journal-title":"Blood Cancer J"},{"issue":"17","key":"3715_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70014","volume":"131","author":"MB Nierengarten","year":"2025","unstructured":"Nierengarten MB. Recommendations highlight important updates specific to systemic therapy options for those with newly diagnosed or previously treated multiple myeloma. Cancer. 2025;131(17):e70014.","journal-title":"Cancer"},{"key":"3715_CR83","doi-asserted-by":"crossref","unstructured":"Rifkin R, Schade H, Simmons G, et al. OPTec: a phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM): updated results. Presented at the 66th American Society of Hematology (ASH) Annual Meeting; December 7\u201310, 2024; San Diego, CA, USA.","DOI":"10.1182\/blood-2024-207295"},{"issue":"suppl 1","key":"3715_CR84","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1182\/blood-2024-203379","volume":"144","author":"TC Beer","year":"2024","unstructured":"Beer TC, Graf GHJ, Lin D, et al. Dosing patterns and early safety and effectiveness outcomes in patients with multiple myeloma treated with teclistamab in the community setting. Blood. 2024;144(suppl 1):2398\u20139.","journal-title":"Blood"},{"issue":"suppl 1","key":"3715_CR85","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2024-209008","volume":"144","author":"A Afrough","year":"2024","unstructured":"Afrough A, Khan AM, Chinaeke E, et al. Real-world characteristics and outcomes in patients with multiple myeloma receiving teclistamab step-up doses in academic vs. community settings. Blood. 2024;144(suppl 1):933\u20134.","journal-title":"Blood"},{"issue":"suppl 1","key":"3715_CR86","doi-asserted-by":"publisher","first-page":"7851","DOI":"10.1182\/blood-2024-210497","volume":"144","author":"Y Levy","year":"2024","unstructured":"Levy Y, Kim N, Mahmud S, et al. Real-world characteristics, step-up dosing patterns, and outcomes in patients with multiple myeloma receiving teclistamab at Texas oncology community-based treatment centers. Blood. 2024;144(suppl 1):7851\u20132.","journal-title":"Blood"},{"issue":"suppl 2","key":"3715_CR87","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S2152-2650(24)01938-4","volume":"24","author":"R Jiwani","year":"2024","unstructured":"Jiwani R, Maples S, DiLeo R, et al. Can bispecific T cell engagers for multiple myeloma be safely administered in the community? A single center experience. Clin Lymphoma Myeloma Leuk. 2024;24(suppl 2):S61.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"3715_CR88","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1182\/blood-2024-208825","volume":"144","author":"L Herms","year":"2024","unstructured":"Herms L, Su Z, Paulus J, et al. Real-world utilization of bispecific antibodies for treatment of relapsed\/refractory multiple myeloma in the US community oncology setting. Blood. 2024;144(suppl 1):2410\u20131.","journal-title":"Blood"},{"issue":"1","key":"3715_CR89","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14(1):158.","journal-title":"Blood Cancer J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03715-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03715-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03715-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:18Z","timestamp":1794254598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03715-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":89,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3715"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03715-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ajay K Nooka served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BeyondSpring Pharmaceuticals, Bristol Myers Squibb, Cellectar Biosciences, Genzyme, GSK, Janssen Oncology, Karyopharm Therapeutics, Oncopeptides, ONK Therapeutics, Pfizer, Secura Bio, and Takeda; received travel, accommodations, or expenses from GSK; received honoraria from Adaptive Biotechnologies, Amgen, Bristol Myers Squibb\/Celgene, Cellectar Biosciences, GSK, Janssen Oncology, K36 Therapeutics, ONK Therapeutics, Pfizer, Secura Bio, and Takeda; and received research funding from Amgen, Arch Oncology, Bristol Myers Squibb\/Celgene, Cellectar Biosciences, GSK, Janssen Oncology, Pfizer, and Takeda. Margaret Doyle is employed by and may have stock\/other ownership interests in Johnson & Johnson. Roberto Mina served in a consulting or advisory role for AbbVie, Bristol Myers Squibb, GSK, Janssen-Cilag EMEA, Janssen Pharmaceuticals, Pfizer, Sanofi, and Takeda; and received honoraria from AbbVie, Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Pfizer, Roche, and Sanofi.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This podcast article is based on previously published work and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}